vs
ASP Isotopes Inc.（ASPI）与RYTHM, Inc.（RYM）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是RYTHM, Inc.的1.6倍（$16.7M vs $10.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 242.0%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
RYTHM Inc.是一家临床阶段生物制药企业，专注于研发和商业化针对罕见遗传性内分泌与代谢疾病的创新疗法，主要面向美国市场，服务存在未被满足医疗需求的儿童及成人患者群体。
ASPI vs RYM — 直观对比
营收规模更大
ASPI
是对方的1.6倍
$10.7M
营收增速更快
ASPI
高出1053.7%
242.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $10.7M |
| 净利润 | — | $-13.6M |
| 毛利率 | 12.5% | 75.5% |
| 营业利润率 | — | -121.5% |
| 净利率 | — | -127.6% |
| 营收同比 | 1295.7% | 242.0% |
| 净利润同比 | -586.8% | 44.1% |
| 每股收益（稀释后） | — | $-6.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIRYM
| Q4 25 | $16.7M | $10.7M | ||
| Q3 25 | $4.9M | $4.0M | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | — | $538.0K | ||
| Q4 24 | — | $-7.5M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | — | $3.0M | ||
| Q1 24 | — | $2.6M |
净利润ASPIRYM
| Q4 25 | — | $-13.6M | ||
| Q3 25 | $-12.9M | $-10.7M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-24.4M | ||
| Q3 24 | — | $-18.7M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | — | $4.2M |
毛利率ASPIRYM
| Q4 25 | 12.5% | 75.5% | ||
| Q3 25 | 8.7% | 34.0% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 16.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | — | 37.6% | ||
| Q1 24 | — | 6.4% |
营业利润率ASPIRYM
| Q4 25 | — | -121.5% | ||
| Q3 25 | -306.1% | -219.8% | ||
| Q2 25 | — | -332.9% | ||
| Q1 25 | — | -687.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -63.1% | ||
| Q2 24 | — | -28.5% | ||
| Q1 24 | — | 13.6% |
净利率ASPIRYM
| Q4 25 | — | -127.6% | ||
| Q3 25 | -263.7% | -263.8% | ||
| Q2 25 | — | -360.4% | ||
| Q1 25 | — | -302.2% | ||
| Q4 24 | — | 324.4% | ||
| Q3 24 | — | -964.4% | ||
| Q2 24 | — | -99.3% | ||
| Q1 24 | — | 163.0% |
每股收益（稀释后）ASPIRYM
| Q4 25 | — | $-6.78 | ||
| Q3 25 | $-0.15 | $-5.33 | ||
| Q2 25 | — | $-3.74 | ||
| Q1 25 | — | $-0.83 | ||
| Q4 24 | — | $-24.26 | ||
| Q3 24 | — | $-17.28 | ||
| Q2 24 | — | $-3.16 | ||
| Q1 24 | — | $3.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $32.2M |
| 总债务越低越好 | $14.4M | $80.6M |
| 股东权益账面价值 | $204.2M | $13.0M |
| 总资产 | $498.0M | $106.7M |
| 负债/权益比越低杠杆越低 | 0.07× | 6.19× |
8季度趋势，按日历期对齐
现金及短期投资ASPIRYM
| Q4 25 | $333.3M | $32.2M | ||
| Q3 25 | $113.9M | — | ||
| Q2 25 | — | $41.0M | ||
| Q1 25 | — | $24.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $267.0K | ||
| Q2 24 | — | $57.0K | ||
| Q1 24 | — | $99.0K |
总债务ASPIRYM
| Q4 25 | $14.4M | $80.6M | ||
| Q3 25 | $13.9M | $90.6M | ||
| Q2 25 | — | $40.6M | ||
| Q1 25 | — | $10.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $4.6M | ||
| Q1 24 | — | — |
股东权益ASPIRYM
| Q4 25 | $204.2M | $13.0M | ||
| Q3 25 | $74.1M | $11.7M | ||
| Q2 25 | — | $21.0M | ||
| Q1 25 | — | $26.8M | ||
| Q4 24 | — | $28.1M | ||
| Q3 24 | — | $5.5M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $-5.5M |
总资产ASPIRYM
| Q4 25 | $498.0M | $106.7M | ||
| Q3 25 | $225.9M | $115.2M | ||
| Q2 25 | — | $69.5M | ||
| Q1 25 | — | $45.6M | ||
| Q4 24 | — | $54.0M | ||
| Q3 24 | — | $39.0M | ||
| Q2 24 | — | $39.4M | ||
| Q1 24 | — | $40.6M |
负债/权益比ASPIRYM
| Q4 25 | 0.07× | 6.19× | ||
| Q3 25 | 0.19× | 7.73× | ||
| Q2 25 | — | 1.94× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-3.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIRYM
| Q4 25 | $-37.8M | $-3.0M | ||
| Q3 25 | $-8.9M | $-5.4M | ||
| Q2 25 | — | $-8.4M | ||
| Q1 25 | — | $-6.7M | ||
| Q4 24 | — | $-5.3M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-3.0M |
自由现金流ASPIRYM
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-3.0M |
自由现金流率ASPIRYM
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -61.2% | ||
| Q1 24 | — | -115.1% |
资本支出强度ASPIRYM
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
现金转化率ASPIRYM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
RYM
| Nonlicensing Revenue | $9.5M | 89% |
| Cultivation Business Discontinued Operations | $1.2M | 11% |
